Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.31 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL426332 | 0.97 | CHRNA10 (0.33) | TRIM24TRIM33CHRNA10CHRNA9 | |
| Hydrochloric Acid SCHEMBL7493640 | 0.97 | TRIM24 (0.30) | TRIM24TRIM33CHRNA10CHRNA9 | |
| Bromide SCHEMBL4087944 | 0.97 | TRIM24 (0.30) | TRIM24TRIM33CHRNA10CHRNA9 | |
| SCHEMBL4091649 | 0.87 | — | — | |
| Sulfuric Acid SCHEMBL4083513 | 0.85 | — | — | |
| SCHEMBL4083156 | 0.82 | — | — | |
| SCHEMBL10256575 | 0.80 | — | — | |
| SCHEMBL4078041 | 0.76 | CYP2C9 (0.38) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3728468 | 0.74 | CHRNA7 (0.33) | TRIM24TRIM33CHRNA10CHRNA9ALDH1A1 | |
| Bromide SCHEMBL3741619 | 0.74 | CHRNA7 (0.33) | TRIM24TRIM33CHRNA10CHRNA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| WO-2007142585-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1678177-B1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007107567-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107566-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107565-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | NPY4R, NPY1R, OXER1 | TRIM24 3575/4885TRIM33 4583/4885CHRNA10 139/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | TRIM24 4704/4885TRIM33 4769/4885CHRNA10 3623/4885 |
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | TRIM24 2786/4885TRIM33 3556/4885CHRNA10 3087/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | TRIM24 4863/4885TRIM33 4877/4885CHRNA10 273/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | TRIM24 4842/4885TRIM33 4875/4885CHRNA10 384/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | TRIM24 3316/4885TRIM33 4014/4885CHRNA10 3125/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | TRIM24 2657/4885TRIM33 4478/4885CHRNA10 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.